Leerink Partnrs Analysts Cut Earnings Estimates for Cencora

Cencora, Inc. (NYSE:COR) – Leerink Partnrs lowered their Q2 2025 earnings per share (EPS) estimates for Cencora in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $4.08 per share for the quarter, down from their prior forecast of $4.23. The consensus estimate for Cencora’s current full-year earnings is $15.36 per share. Leerink Partnrs also issued estimates for Cencora’s Q4 2025 earnings at $3.82 EPS.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%.

A number of other research analysts also recently issued reports on the stock. Mizuho started coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective for the company. Barclays upped their price target on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Wells Fargo & Company raised their price objective on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 29th. UBS Group upped their target price on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, Robert W. Baird raised their price target on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $277.90.

Cencora Stock Performance

Shares of Cencora stock opened at $246.86 on Monday. The company has a market capitalization of $47.71 billion, a PE ratio of 35.11, a P/E/G ratio of 1.49 and a beta of 0.49. The company has a 50-day simple moving average of $238.86 and a two-hundred day simple moving average of $237.03. Cencora has a one year low of $214.77 and a one year high of $262.26. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.53 and a current ratio of 0.92.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be paid a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. The ex-dividend date is Friday, February 14th. Cencora’s payout ratio is 31.29%.

Insider Buying and Selling

In other news, Chairman Steven H. Collis sold 50,000 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the completion of the transaction, the chairman now owns 326,557 shares of the company’s stock, valued at $79,670,111.29. The trade was a 13.28 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the firm’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 73,187 shares of company stock valued at $17,790,912 over the last quarter. 10.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Cencora

Several hedge funds have recently bought and sold shares of COR. JFS Wealth Advisors LLC increased its holdings in shares of Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after purchasing an additional 46 shares in the last quarter. SBI Securities Co. Ltd. acquired a new stake in Cencora during the fourth quarter valued at $30,000. Concord Wealth Partners purchased a new position in Cencora in the third quarter valued at $30,000. Kentucky Trust Co acquired a new position in shares of Cencora in the fourth quarter worth about $33,000. Finally, Householder Group Estate & Retirement Specialist LLC boosted its stake in shares of Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock worth $33,000 after acquiring an additional 69 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.